Colleges
Adrian Hill
Director of the Jenner Institute, Lakshmi Mittal & Family Professor of Vaccinology, Professor of Human Genetics
Vaccines for malaria and other major diseases
Adrian V. S. Hill KBE, FRCP, FRS is the Lakshmi Mittal Professor of Vaccinology and Director of the Jenner Institute at Oxford University. In 2005 he founded the Jenner Institute at Oxford, which is now one of the largest academic vaccine centres globally with clinical-stage vaccine programmes against fifteen diseases.
His current lead malaria vaccine, R21 in matrix-M adjuvant, has shown high efficacy in clinical trials in the UK and Africa (Lancet. 2021;397:1809-1818) and could be the first widely used vaccine to impact on the great disease burden of malaria in Africa.
In Q1 2020, the Jenner Institute initiated a major effort towards rapid development of a COVID-19 vaccine which in collaboration with AstraZeneca is now in world-wide pandemic deployment.
He has published over 600 research papers with 60,000 citations and co-founded several spin-off companies. He is a Fellow of the UK Academy of Medical Sciences, the Royal College of Physicians and the Royal Society.
Recent publications
Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial
Journal article
Kapulu MC. et al, (2026), Nature Medicine, 32, 178 - 185
Corrigendum to "Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM" [Vaccine 68 (2025) 127897].
Journal article
Mukhopadhyay ES. et al, (2026), Vaccine, 69
Naturally acquired immune responses to alpha-gal in malaria endemic settings and pre-clinical efficacy testing with R21/MM
Journal article
Mukhopadhyay ES. et al, (2025), Vaccine, 68, 127897 - 127897
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
Journal article
Anywaine Z. et al, (2025), The Lancet. Infectious diseases
Subcutaneous administration of the malaria R21/Matrix M vaccine and immune complex formation with anti-circumsporozoite protein mAb 2A10 elicit protective efficacy in mice
Journal article
Mukhopadhyay E. et al, (2025), Frontiers in Immunology, 16